JPWO2021127214A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021127214A5 JPWO2021127214A5 JP2022537683A JP2022537683A JPWO2021127214A5 JP WO2021127214 A5 JPWO2021127214 A5 JP WO2021127214A5 JP 2022537683 A JP2022537683 A JP 2022537683A JP 2022537683 A JP2022537683 A JP 2022537683A JP WO2021127214 A5 JPWO2021127214 A5 JP WO2021127214A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- salt
- preparing
- converted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 136
- 238000000034 method Methods 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 36
- 239000002904 solvent Substances 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 6
- 230000008878 coupling Effects 0.000 claims 6
- 238000010168 coupling process Methods 0.000 claims 6
- 238000005859 coupling reaction Methods 0.000 claims 6
- 239000003054 catalyst Substances 0.000 claims 4
- 208000037262 Hepatitis delta Diseases 0.000 claims 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- 229940126214 compound 3 Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 125000006242 amine protecting group Chemical group 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000368 destabilizing effect Effects 0.000 claims 2
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000011097 chromatography purification Methods 0.000 claims 1
- 238000004440 column chromatography Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- -1 nitrobenzyloxycarbonyl Chemical group 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951836P | 2019-12-20 | 2019-12-20 | |
| US62/951,836 | 2019-12-20 | ||
| PCT/US2020/065666 WO2021127214A1 (en) | 2019-12-20 | 2020-12-17 | Synthetic processes and intermediates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510109A JP2023510109A (ja) | 2023-03-13 |
| JPWO2021127214A5 true JPWO2021127214A5 (pt) | 2023-12-25 |
Family
ID=76478539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537683A Pending JP2023510109A (ja) | 2019-12-20 | 2020-12-17 | 合成プロセス及び中間体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230113948A1 (pt) |
| EP (1) | EP4077473A4 (pt) |
| JP (1) | JP2023510109A (pt) |
| KR (1) | KR20220119052A (pt) |
| CN (1) | CN114846051A (pt) |
| AU (1) | AU2020408039A1 (pt) |
| BR (1) | BR112022012226A2 (pt) |
| CA (1) | CA3165101A1 (pt) |
| IL (1) | IL294064A (pt) |
| MX (1) | MX2022007738A (pt) |
| TW (1) | TW202136227A (pt) |
| WO (1) | WO2021127214A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023143374A1 (zh) * | 2022-01-30 | 2023-08-03 | 成都凌泰氪生物技术有限公司 | 一种配体、其制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0505969D0 (en) * | 2005-03-23 | 2005-04-27 | Novartis Ag | Organic compounds |
| JP2014512364A (ja) * | 2011-04-07 | 2014-05-22 | コーネル ユニバーシティー | 水溶液中で二量体化できる単量体、およびその使用法 |
| MA45478A (fr) * | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| CA3059426A1 (en) * | 2017-04-11 | 2018-10-18 | Arbutus Biopharma Corporation | Targeted compositions |
| KR20210120988A (ko) * | 2018-11-02 | 2021-10-07 | 제네반트 사이언시즈 게엠베하 | 치료 방법 |
-
2020
- 2020-12-17 WO PCT/US2020/065666 patent/WO2021127214A1/en unknown
- 2020-12-17 CN CN202080089979.8A patent/CN114846051A/zh active Pending
- 2020-12-17 EP EP20903872.8A patent/EP4077473A4/en active Pending
- 2020-12-17 AU AU2020408039A patent/AU2020408039A1/en active Pending
- 2020-12-17 IL IL294064A patent/IL294064A/en unknown
- 2020-12-17 US US17/787,089 patent/US20230113948A1/en active Pending
- 2020-12-17 CA CA3165101A patent/CA3165101A1/en active Pending
- 2020-12-17 KR KR1020227022805A patent/KR20220119052A/ko unknown
- 2020-12-17 BR BR112022012226A patent/BR112022012226A2/pt unknown
- 2020-12-17 MX MX2022007738A patent/MX2022007738A/es unknown
- 2020-12-17 JP JP2022537683A patent/JP2023510109A/ja active Pending
- 2020-12-18 TW TW109145121A patent/TW202136227A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024056918A (ja) | キナーゼを修飾する１ｈ－ピロロ［２，３－ｂ］ピリジン誘導体の合成 | |
| ES2655518T3 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis B | |
| JP3590643B2 (ja) | ７−（置換された）−９−［（置換されたグリシル）アミド］−６−デメチル−６−デオキシテトラサイクリン類の製造方法 | |
| TWI762003B (zh) | 抗病毒化合物之合成 | |
| JP2004506611A5 (pt) | ||
| JPWO2021089873A5 (pt) | ||
| JP2020505404A5 (pt) | ||
| JPS6023370A (ja) | グアニジン化合物の製法 | |
| CN1817853A (zh) | 制备苯基丙氨酸衍生物的方法和其中间体 | |
| JP2009534361A5 (pt) | ||
| JP3677790B2 (ja) | ヌクレオシド誘導体とその製造方法 | |
| JPWO2021127214A5 (pt) | ||
| WO2021127214A4 (en) | Synthetic processes and intermediates | |
| JP7278775B2 (ja) | 長鎖化合物の製造方法 | |
| JP4934292B2 (ja) | ５−アミノレブリン酸エステルリン酸類塩、その製造方法及びその用途 | |
| JP2006512364A5 (pt) | ||
| AP1182A (en) | Proces for the synthesis of chloropurine intermediates. | |
| JP2010535185A (ja) | アルフゾシン塩酸塩の製造方法 | |
| JP5520816B2 (ja) | アミンおよびアミンオキシドで開始するアルキルホスフィン酸の合成方法 | |
| JP2020536870A5 (pt) | ||
| WO2012146085A1 (zh) | 用于合成前列腺素类药物的中间体及其制备方法 | |
| CN1373752A (zh) | 前列腺素衍生物 | |
| TW201028384A (en) | Stereoselective synthesis of piperidine derivatives | |
| JPH07238068A (ja) | プロスタグランジンｅ１類縁体 | |
| KR101715682B1 (ko) | 삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법 |